Home LiteratureArticle Details
PMID: 15018846 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Stem cells as a potential treatment of neurological disorders.

Current opinion in pharmacology ·Vol. 4 ·No. 1 ·2004-02-00 ·Pages 98-104

Tai YT, Svendsen CN

Abstract

The ability of stem cells to participate in brain repair has been increasingly demonstrated in recent studies. Most investigations have aimed to replace damaged neurons and glia by direct transplantation or recruitment of newly generated cells in the adult. However, functional improvements were often a result of stem cell-induced self-repair and neuroprotection, rather than cell replacement. Thus, a far more pragmatic approach in the short term might be to use stem cells as chaperones for degenerating nervous tissues. Additionally, targeted delivery of therapeutic agents could be achieved by modifying stem cells to release specific drugs at the site of transplantation. Elucidation and exploitation of this new 'stem cell pharmacology' has the potential to revolutionise treatment of neurological diseases.

MeSH Terms
Animals Humans Models, Animal Models, Neurological Nervous System Diseases/therapy Stem Cell Transplantation/methods Stem Cells/metabolism,physiology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Tai Yu-Tzu
Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Cambridge, UK.
Svendsen Clive N
Article Info
Journal
Current opinion in pharmacology
Abbr.
Curr Opin Pharmacol
ISSN
1471-4892
Published
2004-02-00
Pages
98-104
Language
English
Region
England
NLM ID
100966133
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com